论文部分内容阅读
BABSTRACTackground Nonmyeloablative allogeneic bone marrow transplantation has been used since the 1990s as a new hematological stem cell transplantation strategy for treating hematological diseases. The purpose of this study was to explore the graft-versus-leukemia (GVL) effects of donor lymphocyte infusions (DLIs) after nonmyeloablative allogeneic bone marrow transplantations, while assessing the declines in treatment-associated morbidity, mortality, and graft-versus-host disease (GVHD).Methods A total of 615 (H-2~k) mice were injected with L615 tumor cells and received 500 cGy (~(60)Coγ-ray) irradiation three days later, followed by an allogeneic bone marrow transplantation (allo-BMT). The allo-grafts consisted of 3×10~7 bone marrow cells and 1×10~7 spleen cells from BALB/C (H-2~d) donor mice. Two days after the allo-BMT, the recipient mice were given 200 mg/kg of cyclophosphamide. Subsequently, recipient mice were infused with either donor spleen cells (2×10~7) on day 14 or 21, or donor spleen ce
The purpose of this study was to explore the graft-versus-leukemia (GVL) effects of donor lymphocyte infusions (DLIs) after nonmyeloablative allogeneic bone marrow transplants, while assessing the declines in treatment-associated morbidity, mortality, and graft-versus-host disease (GVHD). Methods A total of 615 (H-2- k) mice were injected with L615 tumor cells and received 500 cGy (~ (60) Coγ-ray) irradiation three days later followed by an allogeneic bone marrow transplantation (allo-BMT). The allo-grafts consisted of 3 × 10 ~ 7 bone marrow cells and 1 × 10 ~ 7 Two days after the allo-BMT, the recipient mice were given 200 mg / kg of cyclophosphamide. Spleen cells from BALB / C (H-2 ~ d) donor mice. 10 ~ 7) on day 14 or 21, or donor spleen ce